BioStem Technologies to Present at the 2024 Planet MicroCap Showcase
April 25, 2024 08:00 ET
|
Biostem Technologies
BioStem Technologies to Present at the 2024 Planet MicroCap Showcase
Promising perspectives for the application of SDS Optic’s inPROBE technology platform for protein expression determination
April 25, 2024 08:00 ET
|
SDS Optic S.A.
SDS Optic's positive results from the Part I Clinical Trial of the novel optic fiber probe, inPROBE®, in vivo real-time molecular diagnostic technology.
Global Bionic Devices Industry Research, 2023-2024 & 2030: Addressing Diverse Healthcare Needs Worldwide to Sustain Growth and Fuel Develoments
April 25, 2024 05:29 ET
|
Research and Markets
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Global Bionic Devices Market, By Product, By Fixation, By Technology, By End User, Country Wise Market Analysis, Key Company Profiles, Trends and...
Cytokinetics to Announce First Quarter Results on May 8, 2024
April 24, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00...
Mass Spectrometry Market Size to Reach USD 12.3 Billion By 2032, at 8.8% CAGR: Dimension Market Research
April 24, 2024 12:40 ET
|
Dimension Market Research
New York, April 24, 2024 (GLOBE NEWSWIRE) -- Overview The Global Mass Spectrometry Market was valued of USD 5.7 billion in 2023 which is further expected to reach USD 12.3 billion by the year...
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange
April 24, 2024 08:00 ET
|
Biostem Technologies
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
April 24, 2024 07:00 ET
|
atai Life Sciences
The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the recently...
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
April 24, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Active Pharmaceutical Ingredient Market Trends Signal Growth Towards USD 446.6 Billion by 2032 With CAGR AT 6.4%
April 23, 2024 12:43 ET
|
Dimension Market Research
New York, April 23, 2024 (GLOBE NEWSWIRE) -- Overview According to Dimension Market Research, The Global Active Pharmaceuticals Ingredient Market size was valued USD 249.0 billion in 2023 and it...
Keiretsu Forum Regions Demonstrate Investment Stability Amidst Industry-Wide Downturns
April 23, 2024 07:29 ET
|
Keiretsu Forum Mid-Atlantic
In 2023, Keiretsu Forum MA-SE-TX region’s curated investment portfolio maintained a confident stance within an otherwise retreating investment ecosystem.